Pacific studies

From Blue Pacific to Indo-Pacific: how politics and language define our ‘Indigenous ocean’

Retrieved on: 
Tuesday, January 2, 2024

They announced the way forward as the “Blue Pacific – Our Sea of Islands, Our Livelihoods, Our Oceania”.

Key Points: 
  • They announced the way forward as the “Blue Pacific – Our Sea of Islands, Our Livelihoods, Our Oceania”.
  • It’s a revealing example of how the study of the Pacific and the practice of Pacific politics often intersect.
  • Rapidly, the Blue Pacific – a story about a place – had become a new place.
  • Regional organisations connected through the Blue Pacific, and it became a cornerstone of diplomatic and national language.

New names, old stories

  • Holding together the new movement – which was launched at a moment of considerable difficulty for the region – was an old story.
  • The Forum leaders and others around it explicitly referred to the Blue Pacific as a narrative.
  • As the Samoan Prime Minister put it, “[t]he Blue Pacific provides a new narrative for Pacific Regionalism and how the Forum engages with the world”.

The Indo-Pacific as geopolitical construct

  • The Indo-Pacific is now a geopolitical construct said to encompass the Indian Ocean, the South China Sea, and shifting, unspecified parts of the Pacific Ocean.
  • In other words, it both marginalises and co-opts the Indigenous Pacific of which I write.
  • Read more:
    Australia has long viewed the Pacific as a place of threats that must be contained.
  • Such is the power of this particular narrative and construct that it is central to many of the most vital geopolitical discourses and activities globally.

An unequal ocean

  • Though there is a vibrancy to Indigenous traditions and narration, they do not have the same access and circulation; the Pacific remains an unequal ocean.
  • In very few areas is this not apparent, but I wish to draw attention to one specific way in which the colonial, and particularly the decolonising experience, shaped the unequal oceanscapes of the present: mobility.
  • The terms and conditions of formal decolonisation – what I think of as the decolonising bargain – was a bargain struck in profoundly unequal times and in unequal ways, where much of the power lay with former colonial rulers and international players.

‘New blackbirds’

  • The Pacific diaspora, so deeply conditioned by the decolonising bargain, has not mattered equally to Pacific nations recently.
  • In smaller islands and nations these opportunities have seen mobility on remarkable scales; Niue is perhaps the most striking.
  • Since the 1970s the number of Niueans in Niue has declined by around two-thirds, falling from over 5,000 to less than 2,000.
  • As elsewhere in the former (or, as some might contend, currently) colonised world, the visible benefits of colonialism are not readily evident.

Mobility and sovereignty

  • In each of these places, Indigenous Pacific migrants experience outcomes that more closely match their Indigenous neighbours than those of Pākehā/Papālagi/white populations.
  • There are also other costs that these Indigenous Pacific people confront — paid in language, culture, well-being, identity, independence and sovereignty.
  • The transnational dimensions wrought by those Indigenous folks afforded mobility are profound.
  • As Epeli Hau‘ofa so powerfully put it, these Pacific peoples can craft lives that resonate with the mobility of the ancestors.
  • But the majority of Pacific peoples do not have access to transnational mobility.


Damon Salesa does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

Retrieved on: 
Tuesday, November 21, 2023

Longboard will also host a scientific exhibit with members of its leadership team to highlight details of the ongoing PACIFIC study, and to discuss LP352 as a potential best-in-class therapy for people living with rare seizure disorders.

Key Points: 
  • Longboard will also host a scientific exhibit with members of its leadership team to highlight details of the ongoing PACIFIC study, and to discuss LP352 as a potential best-in-class therapy for people living with rare seizure disorders.
  • “We believe that LP352 has the promise to be a best-in-class therapy for a broad range of DEEs, and we remain committed to moving the space forward.
  • We look forward to presenting new posters and hosting a scientific exhibit to highlight the differentiating qualities of LP352 and our unique development plan.
  • I am also pleased to continue our work with key advocacy organizations, including participation in the Rare Epilepsy Network’s panel: Clustering Rare Epilepsies for Research, Trials & Care,” stated Dr. Randall Kaye, Longboard’s Chief Medical Officer.

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.
  • “We look forward to PACIFIC Study topline data in January 2024 evaluating LP352 in people living with Developmental and Epileptic Encephalopathies, or DEEs.
  • DEE caregivers and healthcare providers continue to be frustrated with the lack of new treatment options and remain focused on finding treatment options that balance safety, efficacy and burden.
  • We look forward to Phase 1 SAD data in the first half of 2024,” stated Kevin R. Lind, Longboard’s President and Chief Executive Officer.

Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023

Retrieved on: 
Thursday, October 5, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the speakers for its upcoming Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352, a first-in-class 5-HT2C receptor superagonist in development for the potential treatment of seizures associated with DEEs.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the speakers for its upcoming Investor & Analyst Event focused on the Developmental and Epileptic Encephalopathy (DEE) landscape and LP352, a first-in-class 5-HT2C receptor superagonist in development for the potential treatment of seizures associated with DEEs.
  • *In-person attendance is limited to invited research analysts and institutional investors only.
  • All other guests are invited to view the live or archived webcast virtually on the Investor Relations section of Longboard’s website at https://www.longboardpharma.com/ .
  • The archived webcast will be available for at least 30 days following the event.

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023

Retrieved on: 
Tuesday, September 19, 2023

The event will feature DEE thought leaders who will discuss the unmet medical need and current and emerging treatment landscape for people living with refractory epilepsies.

Key Points: 
  • The event will feature DEE thought leaders who will discuss the unmet medical need and current and emerging treatment landscape for people living with refractory epilepsies.
  • The PACIFIC Study is fully enrolled, and topline data are expected around year-end 2023.
  • All other guests are invited to view the live or archived webcast virtually on the Investor Relations section of Longboard’s website at https://www.longboardpharma.com/ .
  • The archived webcast will be available for at least 30 days following the event.

Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

Retrieved on: 
Wednesday, August 23, 2023

The primary objectives of the study are to assess the safety and tolerability of LP352.

Key Points: 
  • The primary objectives of the study are to assess the safety and tolerability of LP352.
  • The PACIFIC Study will also evaluate change in seizure frequency over the treatment period, and data are expected to inform the design and characteristics of the planned Phase 3 program for LP352.
  • Participants who complete the PACIFIC Study are eligible to roll over into the ongoing open-label extension trial should they choose to do so.
  • “There is a dire need for continued improvement in research and innovation for these severe syndromes, and we are looking forward to the outcome of the PACIFIC Study.”

Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.
  • “We have made great progress in the first half of 2023 and look forward to completing enrollment for the PACIFIC Study in the coming weeks resulting in topline data around the end of this year.
  • “We also look forward to making advances on LP659, our centrally acting, S1P receptor subtypes 1 and 5 modulator.”
    SECOND QUARTER 2023 FINANCIAL RESULTS:
    At June 30, 2023, Longboard’s cash, cash equivalents and short-term investments were approximately $63.0 million.
  • The net increase of $0.5 million is primarily related to a $0.4 million increase in personnel-related expenses.

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2023.
  • “We are pleased with the excitement for the PACIFIC Study as we progress towards full enrollment and prepare for topline Phase 1b/2a data for LP352 in the fourth quarter of 2023.
  • We are enthusiastic about moving LP659 into clinical studies as we believe that it could be transformative in a number of neuroinflammatory conditions.”
    FIRST QUARTER 2023 FINANCIAL RESULTS:
    At March 31, 2023, Longboard’s cash, cash equivalents and short-term investments were approximately $76.1 million.
  • General and administrative expenses were $3.4 million for the three months ended March 31, 2023, an increase of $0.9 million, or 37%, compared to $2.5 million for the three months ended March 31, 2022.

Societal CDMO Selected by Longboard Pharmaceuticals to Provide CDMO Services to Support Clinical Development of LP352

Retrieved on: 
Wednesday, April 5, 2023

SAN DIEGO and GAINESVILLE, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL ), a contract development and manufacturing organization (CDMO), today announced that it has been selected by Longboard Pharmaceuticals, Inc. (NASD: LBPH ) to provide CDMO services.

Key Points: 
  • SAN DIEGO and GAINESVILLE, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL ), a contract development and manufacturing organization (CDMO), today announced that it has been selected by Longboard Pharmaceuticals, Inc. (NASD: LBPH ) to provide CDMO services.
  • The agreement spans a range of Societal CDMO’s offerings including technology transfer and analytical method validation activities to support Longboard’s lead asset, LP352, a 5-HT2C receptor superagonist.
  • “This agreement with Longboard offers an excellent illustration of the strides that Societal CDMO continues to make in establishing itself as a preferred CDMO partner for biopharmaceutical companies developing innovative therapeutic candidates.
  • At the end of the day, that is the mission that drives all members of the Societal CDMO team.”

Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

Retrieved on: 
Tuesday, November 29, 2022

We are committed to improving the lives of people living with rare epilepsies, and are pleased to have a meaningful presence at AES this year.

Key Points: 
  • We are committed to improving the lives of people living with rare epilepsies, and are pleased to have a meaningful presence at AES this year.
  • We look forward to presenting data highlighting the intrinsic characteristics of LP352, as well as hosting discussions around our ongoing PACIFIC study and future development plans.
  • Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs).
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.